Zydus Lifesciences has launched two artificial intelligence-powered continuous glucose monitoring (CGM) devices — Diasens and GlucoLive — expanding its companion diagnostics portfolio as demand grows for smarter chronic disease management tools.
The next-generation devices are designed to support patients with diabetes, chronic kidney disease (CKD) and those undergoing post-transplant care, enabling continuous tracking of blood glucose levels along with remote monitoring by clinicians.
Unlike many existing CGM systems in India that require manual scanning using near-field communication (NFC), the new devices automatically transmit glucose readings to a patient’s smartphone every three minutes, including overnight measurements, allowing uninterrupted monitoring and early detection of abnormal trends.
The system integrates artificial intelligence-based analytics and a clinician monitoring dashboard through the GoodFlip app, developed by healthcare technology firm Digicare Health Solutions (TatvaCare), with which Zydus has partnered for the rollout.
Through the platform, patients can access AI-driven glucose trend analysis, personalised diet and exercise guidance, doctor consultations, diagnostic lab bookings and a consolidated medical record vault within a single application.
According to the company, the AI layer analyses glucose patterns, flags potential hypoglycaemic or hyperglycaemic episodes, and links fluctuations with food intake or physical activity, helping clinicians intervene earlier and adjust treatment more effectively.
India currently has more than 101 million adults living with diabetes and another 136 million in the pre-diabetic stage, according to the ICMR-INDIAB study published in The Lancet Diabetes & Endocrinology. Diabetes is also a leading contributor to chronic kidney disease in the country, with 25–40% of CKD patients having a history of diabetes.
Despite the high disease burden, glucose monitoring in India largely remains episodic, typically limited to finger-prick tests or HbA1c checks every few months, which often leads to gaps in clinical insight.
Zydus said the new AI-enabled CGM system aims to bridge this gap by enabling continuous data capture and building a connected ecosystem linking patients, caregivers and clinicians in real time.
Following the announcement, shares of Zydus Lifesciences closed largely unchanged at ₹915.65, down 0.66% on the NSE.
